FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766916643> ?p ?o ?g. }

• W2766916643 endingPage "102922" @default.
• W2766916643 startingPage "102912" @default.
• W2766916643 abstract "// Elena Ioana Braicu 1, 2 , Silvia Darb-Esfahani 3, 2 , Wolfgang D. Schmitt 3 , Kaisa M. Koistinen 4 , Laura Heiskanen 4 , Päivi Pöhö 5, 6 , Jan Budczies 3 , Marc Kuhberg 1 , Manfred Dietel 3 , Christian Frezza 7 , Carsten Denkert 3 , Jalid Sehouli 1, 2 and Mika Hilvo 4, 5 1 Department of Gynecology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany 2 On Behalf of the Tumor Bank Ovarian Cancer Network, Berlin, Germany 3 Institute of Pathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Tumor bank Ovarian Cancer Network, Berlin, Germany 4 Zora Biosciences Oy, Espoo, Finland 5 VTT Technical Research Centre of Finland, Espoo, Finland 6 Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland 7 MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK Correspondence to: Mika Hilvo, email: mika.hilvo@zora.fi Keywords: lipidomics; biomarker; diagnosis; prognosis; ovarian cancer Received: June 14, 2016      Accepted: October 11, 2017      Published: October 26, 2017 ABSTRACT Ovarian cancer is a very severe type of disease with poor prognosis. Treatment of ovarian cancer is challenging because of the lack of tests for early detection and effective therapeutic targets. Thus, new biomarkers are needed for both diagnostics and better understanding of the cellular processes of the disease. Small molecules, consisting of metabolites or lipids, have shown emerging potential for ovarian cancer diagnostics. Here we performed comprehensive lipidomic profiling of serum and tumor tissue samples from high-grade serous ovarian cancer patients to find lipids that were altered due to cancer and also associated with progression of the disease. Ovarian cancer patients exhibited an overall reduction of most lipid classes in their serum as compared to a control group. Despite the overall reduction, there were also specific lipids showing elevation, and especially alterations in ceramide and triacylglycerol lipid species were dependent on their fatty acyl side chain composition. Several lipids showed progressive alterations in patients with more advanced disease and poorer overall survival, and outperformed CA-125 as prognostic markers. The abundance of many serum lipids correlated with their abundance in tumor tissue samples. Furthermore, we found a negative correlation of serum lipids with 3-hydroxybutyric acid, suggesting an association between decreased lipid levels and fatty acid oxidation. In conclusion, here we present a comprehensive analysis of lipid metabolism alterations in ovarian cancer patients, with clinical implications." @default.
• W2766916643 created "2017-11-10" @default.
• W2766916643 creator A5001906921 @default.
• W2766916643 creator A5002170366 @default.
• W2766916643 creator A5002555374 @default.
• W2766916643 creator A5007480376 @default.
• W2766916643 creator A5007997038 @default.
• W2766916643 creator A5008374205 @default.
• W2766916643 creator A5013887971 @default.
• W2766916643 creator A5033698551 @default.
• W2766916643 creator A5052454978 @default.
• W2766916643 creator A5062149227 @default.
• W2766916643 creator A5062227589 @default.
• W2766916643 creator A5063767941 @default.
• W2766916643 creator A5089035898 @default.
• W2766916643 date "2017-10-26" @default.
• W2766916643 modified "2023-10-16" @default.
• W2766916643 title "High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism" @default.
• W2766916643 cites W1540722338 @default.
• W2766916643 cites W1540976265 @default.
• W2766916643 cites W1904593531 @default.
• W2766916643 cites W1978417221 @default.
• W2766916643 cites W1979282828 @default.
• W2766916643 cites W1980568044 @default.
• W2766916643 cites W2009368567 @default.
• W2766916643 cites W2019708305 @default.
• W2766916643 cites W2020740038 @default.
• W2766916643 cites W2022462471 @default.
• W2766916643 cites W2041237929 @default.
• W2766916643 cites W2048023614 @default.
• W2766916643 cites W2057729851 @default.
• W2766916643 cites W2062494200 @default.
• W2766916643 cites W2098120135 @default.
• W2766916643 cites W2117600467 @default.
• W2766916643 cites W2117692326 @default.
• W2766916643 cites W2123696077 @default.
• W2766916643 cites W2143017330 @default.
• W2766916643 cites W2145126338 @default.
• W2766916643 cites W2149441684 @default.
• W2766916643 cites W2168526937 @default.
• W2766916643 cites W2170417182 @default.
• W2766916643 cites W2171175765 @default.
• W2766916643 cites W2270337160 @default.
• W2766916643 cites W2283847485 @default.
• W2766916643 cites W2344273352 @default.
• W2766916643 cites W2411747436 @default.
• W2766916643 cites W2531949107 @default.
• W2766916643 doi "https://doi.org/10.18632/oncotarget.22076" @default.
• W2766916643 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5732699" @default.
• W2766916643 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29262533" @default.
• W2766916643 hasPublicationYear "2017" @default.
• W2766916643 type Work @default.
• W2766916643 sameAs 2766916643 @default.
• W2766916643 citedByCount "48" @default.
• W2766916643 countsByYear W27669166432018 @default.
• W2766916643 countsByYear W27669166432019 @default.
• W2766916643 countsByYear W27669166432020 @default.
• W2766916643 countsByYear W27669166432021 @default.
• W2766916643 countsByYear W27669166432022 @default.
• W2766916643 countsByYear W27669166432023 @default.
• W2766916643 crossrefType "journal-article" @default.
• W2766916643 hasAuthorship W2766916643A5001906921 @default.
• W2766916643 hasAuthorship W2766916643A5002170366 @default.
• W2766916643 hasAuthorship W2766916643A5002555374 @default.
• W2766916643 hasAuthorship W2766916643A5007480376 @default.
• W2766916643 hasAuthorship W2766916643A5007997038 @default.
• W2766916643 hasAuthorship W2766916643A5008374205 @default.
• W2766916643 hasAuthorship W2766916643A5013887971 @default.
• W2766916643 hasAuthorship W2766916643A5033698551 @default.
• W2766916643 hasAuthorship W2766916643A5052454978 @default.
• W2766916643 hasAuthorship W2766916643A5062149227 @default.
• W2766916643 hasAuthorship W2766916643A5062227589 @default.
• W2766916643 hasAuthorship W2766916643A5063767941 @default.
• W2766916643 hasAuthorship W2766916643A5089035898 @default.
• W2766916643 hasBestOaLocation W27669166431 @default.
• W2766916643 hasConcept C121608353 @default.
• W2766916643 hasConcept C126322002 @default.
• W2766916643 hasConcept C142724271 @default.
• W2766916643 hasConcept C204787440 @default.
• W2766916643 hasConcept C2780427987 @default.
• W2766916643 hasConcept C29456083 @default.
• W2766916643 hasConcept C2992245170 @default.
• W2766916643 hasConcept C3019054536 @default.
• W2766916643 hasConcept C71924100 @default.
• W2766916643 hasConceptScore W2766916643C121608353 @default.
• W2766916643 hasConceptScore W2766916643C126322002 @default.
• W2766916643 hasConceptScore W2766916643C142724271 @default.
• W2766916643 hasConceptScore W2766916643C204787440 @default.
• W2766916643 hasConceptScore W2766916643C2780427987 @default.
• W2766916643 hasConceptScore W2766916643C29456083 @default.
• W2766916643 hasConceptScore W2766916643C2992245170 @default.
• W2766916643 hasConceptScore W2766916643C3019054536 @default.
• W2766916643 hasConceptScore W2766916643C71924100 @default.
• W2766916643 hasIssue "61" @default.
• W2766916643 hasLocation W27669166431 @default.
• W2766916643 hasLocation W27669166432 @default.
• W2766916643 hasLocation W27669166433 @default.
• W2766916643 hasLocation W27669166434 @default.

• next